Retatrutide vs Tesamorelin

Both are studied against body-composition endpoints. Almost nothing else about them lines up.

Retatrutide is a single molecule engineered to bind three receptors — GLP-1, GIP and glucagon. It is the most recently developed compound in this catalogue and the human trial programme behind it is still running. Tesamorelin is a growth-hormone-releasing hormone analogue that already completed its regulatory path in one narrow indication, HIV-associated lipodystrophy, and stopped there.

The choice is between reach and settledness. Retatrutide covers more receptor ground than any incretin before it, and the published human data is correspondingly recent and thin. Tesamorelin covers a single axis, and what sits behind it is finished work with a defined endpoint.

Handling separates them again. Tesamorelin's reconstituted window is 24 hours; retatrutide's is 28 days refrigerated. A larger vial is only an economy if the reconstituted material is used inside its stated window, which is why the sizes column and the price-per-mg column have to be read together rather than one at a time.

We publish no comparison of outcomes between these two compounds, because no head-to-head study exists. Anyone presenting one is extrapolating from unrelated trials. What we can state is what is in the vial, what it costs per milligram, and whether it can be shipped — which is what the table above does, from live catalogue data. Both are supplied for laboratory research only.